ArticleACS omega2021
Gut Bacteria of
Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Glucosamine functionalized multi-walled carbon nanotubes as potential antibacterial molecules.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Azole-based compounds as potential anti-RSC medicinal chemistry · 2024Article
- Selected Gut Bacteria from Water Monitor Lizard Exhibit Effects against PathogenicMicroorganisms · 2023Article
- Antibacterial Properties of Ethacridine Lactate and Sulfmethoxazole Loaded Functionalized Graphene Oxide Nanocomposites.Antibiotics (Basel, Switzerland) · 2023Article
- Microbiome and One Health: Potential of Novel Metabolites from the Gut Microbiome of Unique Species for Human Health.Microorganisms · 2023Article
- Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles.Pathogens and global health · 2022Article
- Antiamoebic Activity of Imidazothiazole Derivatives against Opportunistic PathogenAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Moxifloxacin and Sulfamethoxazole-Based Nanocarriers Exhibit Potent Antibacterial Activities.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among several animals,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.